EP3472316A4 - Anti-c5 antibodies and methods of use - Google Patents

Anti-c5 antibodies and methods of use Download PDF

Info

Publication number
EP3472316A4
EP3472316A4 EP17813418.5A EP17813418A EP3472316A4 EP 3472316 A4 EP3472316 A4 EP 3472316A4 EP 17813418 A EP17813418 A EP 17813418A EP 3472316 A4 EP3472316 A4 EP 3472316A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17813418.5A
Other languages
German (de)
French (fr)
Other versions
EP3472316A1 (en
Inventor
Yoshinao Ruike
Zenjiro Sampei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of EP3472316A1 publication Critical patent/EP3472316A1/en
Publication of EP3472316A4 publication Critical patent/EP3472316A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
EP17813418.5A 2016-06-17 2017-06-16 Anti-c5 antibodies and methods of use Pending EP3472316A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016120325 2016-06-17
PCT/JP2017/022253 WO2017217524A1 (en) 2016-06-17 2017-06-16 Anti-c5 antibodies and methods of use

Publications (2)

Publication Number Publication Date
EP3472316A1 EP3472316A1 (en) 2019-04-24
EP3472316A4 true EP3472316A4 (en) 2020-01-08

Family

ID=59969459

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17813418.5A Pending EP3472316A4 (en) 2016-06-17 2017-06-16 Anti-c5 antibodies and methods of use

Country Status (19)

Country Link
EP (1) EP3472316A4 (en)
JP (3) JP6202774B1 (en)
KR (2) KR101852739B1 (en)
CN (3) CN115960223A (en)
AU (1) AU2017285763B2 (en)
BR (1) BR112018075688A2 (en)
CA (1) CA3021956A1 (en)
CL (1) CL2018003573A1 (en)
CR (1) CR20190013A (en)
EA (1) EA201990018A1 (en)
IL (2) IL300611A (en)
MX (2) MX2018015030A (en)
MY (1) MY187848A (en)
PE (1) PE20190394A1 (en)
PH (1) PH12018502354A1 (en)
SG (2) SG11201705584VA (en)
TW (4) TW202337903A (en)
UA (1) UA126561C2 (en)
WO (1) WO2017217524A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN101874042B9 (en) 2007-09-26 2019-01-01 中外制药株式会社 Method for changing isoelectric point of antibody by using amino acid substitution of CDR
NZ602884A (en) 2008-04-11 2014-08-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
KR102385507B1 (en) 2010-11-30 2022-04-12 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
AU2015365167B2 (en) 2014-12-19 2021-07-29 Chugai Seiyaku Kabushiki Kaisha Anti-C5 antibodies and methods of use
CA3027487A1 (en) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
MY187848A (en) * 2016-06-17 2021-10-26 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
SG11201801024XA (en) 2016-08-05 2018-05-30 Chugai Pharmaceutical Co Ltd Therapeutic or preventive compositions for il-8-related diseases
KR20200059279A (en) * 2017-10-04 2020-05-28 알렉시온 파마슈티칼스, 인코포레이티드 Dosage and administration of anti-C5 antibody for treatment of patients with membranous glomerulonephritis
AU2018383751A1 (en) 2017-12-13 2020-06-25 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
BR112021004141A2 (en) * 2018-09-06 2021-05-25 The Trustees Of The University Of Pennsylvania ph-dependent antibody that specifically binds to human c5, methods of treating a complement pathway mediated disease or disorder in an individual and of reducing the activity of a genetically modified individual, cell, and non-human animal complement system.
AU2020261073A1 (en) * 2019-04-24 2021-12-16 Kira Pharmaceuticals (Us) Llc Bi-functional humanized anti-C5 antibodies and factor H fusion proteins and uses thereof
CN113563467A (en) * 2020-04-28 2021-10-29 上海普铭生物科技有限公司 Antibodies against human complement protein C5 and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016098356A1 (en) * 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0230985Y2 (en) 1985-07-08 1990-08-21
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
DE60143859D1 (en) 2001-06-12 2011-02-24 Ericsson Telefon Ab L M SYNCHRONIZATION IN A TERRESTRIAL UMTS RADIO ACCESS NETWORK (UTRAN)
BRPI0211953B8 (en) 2001-08-17 2021-05-25 Genentech Inc monoclonal antibody or antigen-binding fragment that binds to c5 and c5a without the prevention of c5b formation, cell lineage, pharmaceutical composition, as well as in vitro method to inhibit c5a activity and in vitro diagnostic method
JP4333939B2 (en) 2001-08-27 2009-09-16 ロード・コーポレーション Trolley wire suspension system
DE10253331A1 (en) 2002-11-14 2004-06-03 Symrise Gmbh & Co. Kg Use of trans-pellitori as a flavoring
US7267849B2 (en) 2004-03-02 2007-09-11 Nitto Denko Corporation Compensator for liquid crystal display
KR20080069889A (en) 2007-03-20 2008-07-29 (주)화도 Pe pipe
EP2129681A2 (en) * 2007-03-22 2009-12-09 Novartis Ag C5 antigens and uses thereof
EP2138531B1 (en) 2007-04-11 2014-10-29 Sekisui Chemical Co., Ltd. Method for production of crosslinked polyvinyl acetal resin, and crosslinked polyvinyl acetal resin
NZ602884A (en) * 2008-04-11 2014-08-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
MY159396A (en) * 2008-08-05 2016-12-30 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
KR20100054403A (en) 2008-11-14 2010-05-25 삼성전자주식회사 Online composition apparatus and method for writing by multiple participants
JP5932670B2 (en) * 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション Antibody with pH-dependent antigen binding
TW201206466A (en) * 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding
KR20110111007A (en) 2010-04-02 2011-10-10 이화여자대학교 산학협력단 Octahydro-binaphthol derivatives for l/d optical conversion and optical resolution
KR20110122011A (en) 2010-05-03 2011-11-09 황보철종 System for administrating combine store point and method therefor
TWI596115B (en) * 2012-08-13 2017-08-21 再生元醫藥公司 Anti-pcsk9 antibodies with ph-dependent binding characteristics
AU2014213147B2 (en) * 2013-01-31 2019-01-17 lmmunAbs Inc. C5 antibody and method for preventing and treating complement-related diseases
CA2897334A1 (en) * 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
KR102467124B1 (en) * 2015-12-18 2022-11-15 추가이 세이야쿠 가부시키가이샤 Anti-c5 antibodies and methods of use
MY187848A (en) * 2016-06-17 2021-10-26 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016098356A1 (en) * 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKU FUKUZAWA ET AL: "Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases", SCIENTIFIC REPORTS, vol. 7, no. 1, 24 April 2017 (2017-04-24), XP055399003, DOI: 10.1038/s41598-017-01087-7 *

Also Published As

Publication number Publication date
SG10201800265UA (en) 2018-02-27
TW201809000A (en) 2018-03-16
KR102226975B1 (en) 2021-03-11
JP7032077B2 (en) 2022-03-08
EP3472316A1 (en) 2019-04-24
MX2023001360A (en) 2023-02-27
CA3021956A1 (en) 2017-12-21
TW201808996A (en) 2018-03-16
EA201990018A1 (en) 2019-08-30
JP2018009021A (en) 2018-01-18
IL263657A (en) 2019-01-31
RU2019100222A (en) 2020-07-17
SG11201705584VA (en) 2018-05-30
CR20190013A (en) 2019-03-05
PH12018502354A1 (en) 2019-09-23
TWI807666B (en) 2023-07-01
CN115960223A (en) 2023-04-14
PE20190394A1 (en) 2019-03-13
BR112018075688A2 (en) 2019-04-02
WO2017217524A1 (en) 2017-12-21
MX2018015030A (en) 2019-04-22
CN109312326A (en) 2019-02-05
TW202337903A (en) 2023-10-01
AU2017285763A1 (en) 2018-11-08
KR20190009273A (en) 2019-01-28
CN115925922A (en) 2023-04-07
KR101852739B1 (en) 2018-04-30
JP2022091748A (en) 2022-06-21
UA126561C2 (en) 2022-11-02
IL300611A (en) 2023-04-01
TWI610941B (en) 2018-01-11
MY187848A (en) 2021-10-26
RU2019100222A3 (en) 2020-11-05
AU2017285763B2 (en) 2024-02-01
JP2017226655A (en) 2017-12-28
TWI789369B (en) 2023-01-11
TW202239766A (en) 2022-10-16
CL2018003573A1 (en) 2019-02-01
JP6202774B1 (en) 2017-09-27
CN109312326B (en) 2022-09-09

Similar Documents

Publication Publication Date Title
IL265800A (en) Anti-lag-3 antibodies and methods of use thereof
SG10201912879YA (en) Anti-sirp-alpha antibodies and methods of use thereof
EP3233921A4 (en) Anti-c5 antibodies and methods of use
HUE062927T2 (en) Anti-tigit antibodies and methods of use thereof
EP3515478A4 (en) Antibodies for siglec-15 and methods of use thereof
SG10201912563XA (en) Anti-tim-3 antibodies and methods of use thereof
EP3383430A4 (en) Antibodies and methods of use thereof
EP3454900A4 (en) Cd47 antibodies and methods of use thereof
HUE062436T2 (en) Anti-trem2 antibodies and methods of use thereof
EP3383914A4 (en) Anti-ox40 antibodies and methods of use thereof
EP3280441A4 (en) Anti-sortilin antibodies and methods of use thereof
EP3472316A4 (en) Anti-c5 antibodies and methods of use
EP3390442A4 (en) Anti-c5 antibodies and methods of use
EP3177322A4 (en) Anti-trem2 antibodies and methods of use thereof
EP3472200A4 (en) Anti-myostatin antibodies and methods of use
EP3116911B8 (en) Anti-mcam antibodies and associated methods of use
EP3383917A4 (en) Novel anti-claudin antibodies and methods of use
EP3134121A4 (en) Novel anti-rnf43 antibodies and methods of use
EP3491025A4 (en) Fcrn antibodies and methods of use thereof
EP3280440A4 (en) Humanized anti-c1s antibodies and methods of use thereof
EP3559042A4 (en) Anti-lilrb3 antibodies and methods of use thereof
IL265957A (en) Anti-c1s antibodies and methods of use thereof
EP3189079A4 (en) Novel anti-mfi2 antibodies and methods of use
EP3728323A4 (en) Anti-frizzled antibodies and methods of use
EP3710589A4 (en) Anti-c1s antibodies and methods of use

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191210

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/18 20060101AFI20191204BHEP

Ipc: A61P 7/00 20060101ALI20191204BHEP

Ipc: C12N 15/09 20060101ALI20191204BHEP

Ipc: A61K 39/395 20060101ALI20191204BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220923